Recent Updates
Recently added Catalysts
FATE Negative Sentiment Score: 35/100

FATE THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Key Takeaway: Bragar Eagel & Squire, P.C. is conducting an investigation on behalf of long-term stockholders of Fate Therapeutics following a class action complaint related to the company's actions from April 2020 to January 2023. The investigation focuses on claims regarding alleged breaches of fiduciary duties by the board of directors. This arises after Fate terminated a significant collaboration with Janssen, resulting in a reduction of its workforce and discontinuation of several cancer treatments. The company is facing legal challenges for not disclosing material information to investors during the specified timeframe.

Market Sentiment Analysis

CONCERNS & RISKS

  • Class action lawsuit filed against Fate for failing to disclose material information.
  • Termination of collaboration agreement with Janssen, leading to reduced headcount and discontinued programs.
  • Investigation into the board's potential breach of fiduciary duties to the company.

Full Press Release Details

NEW YORK, Aug. 27, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Fate Therapeutics, Inc. (NASDAQ: FATE) on behalf of long-term stockholders following a class action complaint that was filed against Fate on January 20, 2023 with a Class Period from April 2, 2020 to January 5, 2023. Our investigation concerns whether the board of directors of Fate have breached their fiduciary duties to the company.
On April 2, 2020, the Company announced its entry into a global collaboration and option agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for cell-based cancer immunotherapies, under which Fate received a $50 million upfront payment and was eligible for up to $3 billion in various milestone payments and double-digit royalties on any net sales from the collaboration. Then, on January 5, 2023, the Company disclosed that it had terminated the Janssen Agreement and that all licenses and other rights granted pursuant to the Agreement would terminate, that it would reduce its headcount to about 220 employees in Q1 2023, and that it would discontinue several of its natural cell killer programs in various cancers.
Thereafter, the Company and certain of its executives were sued in a securities class action lawsuit, charging them with failing to disclose material information during the Class Period in violation of federal securities laws, which remains pending.
If you are a long-term stockholder of Fate, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Tags

Frequently Asked Questions

What is the focus of the investigation by Bragar Eagel & Squire?

The investigation focuses on potential claims against Fate Therapeutics concerning breaches of fiduciary duties by its board.

What was the result of the Janssen Agreement for Fate Therapeutics?

Fate received a $50 million upfront payment and could earn up to $3 billion in milestones, but the agreement was terminated in January 2023.

Who can contact Bragar Eagel & Squire for more information?

Long-term stockholders of Fate can contact Brandon Walker or Marion Passmore for more information.

What triggered the class action lawsuit against Fate Therapeutics?

The lawsuit was triggered by allegations that Fate failed to disclose material information during the defined class period.

Does Bragar Eagel & Squire charge for consultations?

No, there is no cost or obligation for long-term stockholders seeking information or assistance.

Last updated: Aug 28, 2023